December 10th & 11th, 2026
15th edition
MARSEILLE, FR

Are immunotherapies still an investment eldorado?

Are immunotherapies still an investment eldorado?

Investment in immunotherapy in 2018 is still attractive and sought out; what is its growth
potential after several years of being an investment blockbuster? What have been the 2018
investment successes in immunotherapy? Will immunotherapy disrupt the oncology market?
Are we at the growth, maturity, or saturation stage when we talk about investing in
immunotherapy?

Chris Shelley

Partner – IP, IT & Commercial
Penningtons Manches Cooper LLP

Khatereh Ahmadi

Head of Search and Evaluation, European BD&L team
MSD

Madiha Derouazi

Founder and CEO
AMAL Therapeutics

Bram Vanparys

Partner – Health & Care
Gimv

Juan García

CEO
BioSeed Capital
Scroll to Top

Before you leave…

Download the official BioFIT 2026 brochure

Discover the conference programme, partnership opportunities, attendee profiles, registration options and everything you need to make the most of BioFIT 2026.